Selvita (SLV) - SEL24 enters Phase I/II

12:57 EDT 20 Mar 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - Selvita: Selvita delivered on both fronts in 2016. We expect sales to have grown a solid 21% y-o-y, with an R&D milestone met and the FDA accepting an investigational new drug application for the company’s lead drug candidate, SEL24, which now proceeds through Phase I/II. We have increased our valuation to PLN577m, which includes the first stage of Selvita’s long-term expansion plans. Continued organic growth and potential collaboration deals for Selvita’s innovation platform are likely catalysts in 2017.

Original Article: Selvita (SLV) - SEL24 enters Phase I/II


More From BioPortfolio on "Selvita (SLV) - SEL24 enters Phase I/II"

Quick Search

Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...